Did you know that SSO’s learning management system, ExpertED@SSO, has had more than 10,000 visits by over 1,200 physicians? If you haven’t visited the site, take a few moments to check out more than 75 educational programs. SSO’s Education Council Vice Chair Glenda Calendar, MD, said, “One activity that I find extremely valuable on ExpertED is the SSO 2018 Virtual Meeting. This is a great way to review session content, or if you didn’t attend the SSO 2018, you have easy access to the most current clinical information.”
Career-long education, recertification and quality patient care make up the strategic plan’s education goal. The SSO Education Council is committed to the development of 50 new educational programs for ExpertED over the next two years. Some of these programs will leverage new research presented during the Annual Cancer Symposium, as well as research published in the Annals of Surgical Oncology. In order to ensure the development of the most relevant programs, the Education Council is comprised of Disease Site Work Group Chairs and members of other SSO Committees and reviews proposals brought forward by internal or external stakeholders.
Listed below are a few upcoming ExpertED@SSO programs that are free to members.
Current Controversies in Neoadjuvant Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer, November 26, 2018 at 5:30 pm EST
This webinar will identify the benefits of neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC), compare options for neoadjuvant therapy and have a better understanding of how to assess current practices. Faculty for this program include Clifford Cho, MD, Theodore S. Hong, MD, Christina R. Ferrone, MD and Robert A. Wolff, MD.
Current Management of the Axilla in Breast Cancer, December 10, 2018 at 6:00 pm EST
Prospective trials have established new options for managing the axillary nodes in patients with breast cancer, but appropriate options vary based on clinical presentation, planned surgical procedure and timing of surgery and chemotherapy. Surgeons need to understand when axillary dissection is indicated for nodal metastases and when sentinel node biopsy alone is appropriate as well as to identify patients most likely to avoid axillary dissection through the use of neoadjuvant therapy. Faculty for this program are: Monica Morrow, MD, Armando Giuliano, MD and Melissa Pilewski, MD.
Adjuvant Therapy in High Risk Melanoma, on December 13, 2018 at 5:00 pm EST
The staging of melanoma has changed and has impact on care decisions, which have evolved across disease stages. Participants in this program will be better able to identify changes in the staging system and understand adjuvant treatment options and proper indications related to BRAF negative patients. Faculty for this program are: Richard White, Jr., MD, Genevieve Boland, MD, PhD, Mary Sue Brady, MD and Jeffrey Sosman, MD.